Type 2 Diabetes

A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

A study from Intermountain Healthcare provides insight into the tolerability and clinical impact and tolerability of initiating combination therapy with both SGLT2 inhibitors and GLP-1 RAs compared against monotherapy with either agent.

Dr. Gregory Weiss discusses prediabetes screening in the US as a method help quell the growing diabetes epidemic in younger populations.

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D.

A discussion into broadening the findings of the SuperWIN trial and its potential effects on a larger, more at-risk population.

Dylan Steen, MD discusses positive findings from the trial on links between personalized education and DASH diet adherence.

We sat down with Deepak Bhatt, MD, MPH, at ACC.22 to discuss a study he took part in assessing the potential patient population of finerenone using eligibility criteria from FIDELIO-DKD and FIGARO-DKD against information from NHANES.

An analysis of Medical Expenditure Panel Survey data suggests minority patients were less likely to undergo recommended exams and more likely to develop diabetic eye complications than their White counterparts.

There are now more insulin options for patients with diabetes than ever before.

Dr. Jabbour discusses unmet needs in diabetes care and starting insulin therapy.

Team-based care shows the reduction of multiple risk factors, attainment of multiple treatment targets, and empowerment among high-risk patients with DKD.

An analysis of more than 100 mother-child pairs from Colorado found children with fetal exposure to cannabis had increased fat mass and fasting glucose levels compared to their counterparts without fetal exposure to cannabis.

The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent regulatory news surrounding CGM devices in the US and Europe.

The therapy is indicated for conditions associated with hypogonadism in adult males.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Data from a new study indicates human behavior and decision-making could be hampering the ability of new diabetes technologies to reduce hypoglycemic events in patients with type 1 diabetes.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. March's month in review features CGM news, calls for insulin co-pay caps, and info on the declining quality of US diets.

Severe and level 2 hypoglycemia has continued to occur in individuals with type 1 diabetes and high hypoglycemia risks despite technological advancements.

Participation in a tele-mentoring program led by Robert Wood Johnson Medical School was associated with a 44% decrease in inpatient admissions and a more than 60% decrease in inpatient spending among Medicaid patients with diabetes.

An analysis of data from 2013-2015 provides insight into the impact of Medicaid expansion under the Affordable Care Act on rate of major diabetes-related amputations and suggests a shift in the distribution of uninsured patients may have driven reductions observed in the study.

An analysis of data from patients with diabetes in VA nursing homes suggests 17% were being overtreated for diabetes and 23% were being potentially overtreated.

An analysis of survey responses from type 1 diabetes caregivers indicates 10.3% of respondents reported job loss, 26.8% reported experiencing financial difficulty, and 71.9% reporting increased stress levels during the pandemic.

Higher BMI in overweight category at midlife was associated with a greater burden of overall and CVD morbidity, as well as higher health care costs in older adulthood.